Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will participate in two virtual investor conferences. Dr. John Houston, President and CEO, will speak at the Guggenheim Targeted Protein Degradation Day on March 16, 2021, and at the 33rd Annual Roth Conference on March 17, 2021. Both panel discussions will be accessible via live audio webcasts on Arvinas’ website, with replays available for 30 days. Arvinas is advancing therapies using its PROTAC® platform to address life-threatening diseases, including prostate and breast cancers.
Arvinas, a clinical-stage biopharmaceutical company, reported its financial results for Q4 and the full year ended December 31, 2020. The company raised $431.9 million from a public stock offering, closing with $688.5 million in cash and equivalents. Q4 revenues decreased to $2.2 million from $4.9 million year-over-year, while total revenue for 2020 was $21.8 million, down from $43.0 million in 2019. A net loss expanded to $41.5 million in Q4, totaling $119.3 million for the year. However, the company noted significant clinical progress in its ARV-471 and ARV-110 programs.
Arvinas, a clinical-stage biopharmaceutical company, announced that its President and CEO, John Houston, and Chief Scientific Officer, Ian Taylor, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on February 11 at 4:30 p.m. ET. The event will be accessible via a live audio webcast on Arvinas’ website. The company focuses on developing innovative therapies that target disease-causing proteins, with ongoing clinical programs for ARV-110 and ARV-471 aimed at treating advanced forms of prostate and breast cancer respectively.
Arvinas, Inc. (Nasdaq: ARVN) announced the full exercise of the underwriter's option to purchase additional shares in its recent public offering, resulting in a total sale of 6,571,428 shares. This offering has generated approximately $431.9 million in net proceeds. Goldman Sachs & Co. LLC and Piper Sandler & Co. managed the offering, with additional support from Cantor Fitzgerald & Co. and BMO Capital Markets. The press release clarifies this is not an offer to sell or solicit any securities unlawfully.
Arvinas, Inc. (Nasdaq: ARVN) has priced a public offering of 5,714,286 shares of its common stock at $70.00 per share, with an option for underwriters to purchase an additional 857,142 shares. This offering is expected to close around December 18, 2020, subject to standard conditions. The funds raised will support Arvinas' efforts in developing targeted protein degradation therapies through its PROTAC® platform, which focuses on treating severe diseases. Goldman Sachs and Piper Sandler are leading the underwriting process.
Arvinas, Inc. (Nasdaq: ARVN) has announced a public offering of $250 million of its common stock, with an additional $37.5 million option for underwriters. Goldman Sachs & Co. LLC and Piper Sandler & Co. are the joint book-running managers. This offering is part of a planned strategy to support Arvinas’ ongoing clinical programs, including its two key candidates: ARV-110 for prostate cancer and ARV-471 for breast cancer. The offering is subject to market conditions and investor interest.
Arvinas, a clinical-stage biopharmaceutical company, announced clinical updates on its PROTAC® protein degraders: ARV-471 and ARV-110. ARV-471 shows potential for best-in-class safety and efficacy in patients with ER+/HER2- breast cancer, demonstrated by a 42% clinical benefit rate and confirmed partial responses. ARV-110 displays anti-tumor activity in men with metastatic castration-resistant prostate cancer, achieving a 40% PSA50 response rate. Both compounds are well tolerated, with ongoing trials expected to advance in 2021, including combination studies.
Arvinas, a clinical-stage biotechnology company, will host a live webcast on December 14, 2020, at 8:00 a.m. ET to present updates on its clinical programs for ARV-471 and ARV-110. The presentation will cover the Phase 1 dose escalation studies for ARV-471 in ER positive/HER2 negative breast cancer and ARV-110 for metastatic castrate-resistant prostate cancer, along with details about the newly initiated Phase 2 dose expansion study for ARV-110.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will present at two virtual investor conferences. The first is the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020, featuring a pre-recorded chat with management. The second conference is the 3rd Annual Evercore ISI HealthCONx Virtual Conference on December 3, 2020, with live participation from key executives. Arvinas is dedicated to developing therapies for debilitating diseases using its proprietary PROTAC® platform, targeting proteins causing various conditions.
Arvinas, a clinical-stage biopharmaceutical firm, announced significant updates in its latest press release. The company has initiated Phase 2 dosing for ARV-110 and continues dose escalation for ARV-110 and ARV-471 trials. A collaboration with Pfizer will lead to a Phase 1b trial combining ARV-471 with Ibrance, expected to start fourth quarter 2020. Financial results for Q3 2020 highlighted a net loss of $30.8 million, an increase from $17.7 million in Q3 2019, amid rising R&D expenses of $30.0 million. Cash reserves were $248.6 million, sufficient to support operations into 2022.